Gene therapy for retinal dystrophy may increase inflammation in some patients

Some patients undergoing voretigene neparvovec treatment for RPE65-related retinal dystrophy may have increased risk of post-treatment inflammation, including those with high BMIs or a family history of inflammatory responses to gene therapy.
Source: AAO

Posted in: Uncategorized

Leave a response

658 Malta Ave, Suite 101 Malta, NY 12020 (518) 580-0553